Vascular Health
Research Study
Research Study
Researchers at the University of Missouri are investigating how a medication can help improve vascular function. Join our compensated study today!
Vascular Health
Research Study
Research Study
Researchers at the University of Missouri are investigating how a medication can help improve vascular function. Join our compensated study today!
Conducted in Columbia, MO
Men & Premenopausal Women 30-70 Years Old
Compensation Provided
No Tobacco Use
Fast Facts
Have Overweight or Obesity
Study Background In general, this research study will measure how a drug called amiloride may impact cardiovascular health among individuals with overweight and obesity. These factors may present an increased risk of blood vessel stiffness, which impedes vascular function. Amiloride is approved by the U.S. Food and Drug Administration (FDA) for use but not specifically for patients with risk factors for blood vessel stiffness. We hope that the information we learn from this study will help us develop better treatments for blood vessel stiffness. Further research on vascular function and join our compensated study today! |
Additional Information
The goal of this study is to determine if a drug, amiloride (that blocks a channel called the epithelial sodium channel), will improve blood vessel stiffness in individuals with overweight and obesity when compared to a placebo.
You may qualify for this study if you meet the following criteria.
Key Criteria:
Key Criteria:
- Men and premenopausal women 30-70 years old
- Have overweight or obesity (BMI between 25.1-50 kg/m2)
- No history of type 1 or 2 diabetes
- No known cardiovascular events in the last 12 months
- Not pregnant, nursing, or planning to become pregnant
- No tobacco use
- No excessive alcohol consumption
The entire study will last up to 6 months and includes 9 lab visits.
- Screening & consent visit (up to 1 hour): vital signs, medical history, height & weight, waist circumference, blood draw, & consent forms
- Baseline visit (up to 6 hours): vital signs, pregnancy test (if applicable), DEXA scan to assess body composition, vascular function measurements, medication, and instructions given
- Dose monitoring visits (up to 30 minutes): vital signs, safety questionnaires, & blood draw to assess kidney function and potassium levels. These occur at 1 week, 4 weeks, 8 weeks, 16 weeks, and 20 weeks after starting medication. Visits at week 8, 16 and 20 may be completed via phone.
- Interim visit (up to 3 hours): blood draw, vital signs, weight, safety questionnaire for side effects, vascular function measurements, pregnancy test (if applicable) & DEXA. This occurs 3 months into the study, and you will receive the next 3 months of medication.
- Final visit (up to 6 hours): vital signs, pregnancy test (if applicable), DEXA scan to assess body composition, vascular function measurements, blood draw for safety labs, waist circumference, safety questionnaire.
Compensation up to $1005 is provided for your participation.
There is no cost for you to participate in this study.
To learn more, please contact Andrea Atkins at muendomanriquelab@health.missouri.edu